Purpose: Although KRAS represents the most commonly mutated oncogene, it has long
been considered an “undruggable” target. Novel covalent inhibitors selective for the …

Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non–small …

Purpose: Covalent inhibitors of KRASG12C specifically target tumors driven by this form of
mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance …

Although KRAS has long been considered undruggable, direct KRAS G12C inhibitors have
shown promising initial clinical efficacy. However, the majority of patients still fail to respond …

KRAS gain-of-function mutations occur in approximately 30% of all human cancers. Despite
more than 30 years of KRAS-focused research and development efforts, no targeted therapy …

KRAS mutations are among the most common drivers of human carcinogenesis, and are
associated with poor prognosis and an aggressive disease course. With the advent of …

Despite the discovery of RAS oncogenes in human tumor DNA 40 years ago, the
development of effective targeted therapies directed against RAS has lagged behind those …

Targeting KRAS mutant tumors through inhibition of individual downstream pathways has
had limited clinical success. Here we report that RAF inhibitors exhibit little efficacy in KRAS …

Activating KRAS mutations are present in 25% of human cancer. Although oncogenic Ras
was deemed" undruggable" in the past, recent efforts led to the development of …

Novel inhibitors targeting Kirsten rat sarcoma virus homolog (KRAS) KRAS G12C in various
cancers have shown good initial efficacy, but therapy-related drug resistance eventually …